In a Phase II trial of treatment-naïve patients with BRAF V600E-mutated NSCLC, treatment with dabrafenib and trametinib resulted in an ORR of 64% and a median PFS of 10.9 months, although 69% of patients experienced at least one grade 3/4 adverse event [136]. Here, BRAF is linked to non-small cell lung carcinoma.